Search

everythinglearnresearchcommunity

for

Search:↓

Early investigation and a team approach are crucial for managing primary amenorrhea effectively.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

The document advises health care providers on how to support transgender and gender-diverse youth with appropriate care and referrals.

Finasteride effectively reduces hair growth in women with polycystic ovary syndrome or idiopathic hirsutism.

Women with PCOS have altered brain structure and reduced cognitive performance.

Female relatives of PCOS patients have a higher chance of showing PCOS symptoms.

The hypothesis suggests that PCOS may start early in life due to genetic and environmental factors, influencing future reproductive and metabolic problems.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

Polycystic Ovary Syndrome likely starts in childhood and may be genetic and influenced by early hormone exposure.

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

Women with epilepsy should be monitored for reproductive issues, which can be caused by epilepsy or its treatments, especially when using valproate.

Women with type 1 diabetes often have polycystic ovary syndrome and excess male hormones, which are frequently undiagnosed.

New hormonal contraceptives are safer, have fewer side effects, and offer health benefits for women.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Certain drugs that block specific enzymes can help treat prostate diseases.

Prolactin may be important for skin growth and immune function.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Certain hormone treatments can improve acne and related conditions in women.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

The document says that understanding the causes of PCOS is important for treatment, especially in distinguishing the syndrome from just having cystic ovaries, and that losing weight is key for obese women with PCOS.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Flutamide works better than finasteride for hirsutism, and combining both is slightly better but not much.

Losing 5-10% body weight can improve PCOS symptoms, letrozole is better than clomiphene for fertility, and managing weight and blood sugar is important to reduce pregnancy complications.

Treating hirsutism in women often requires a mix of medications and cosmetic methods for best results.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Spironolactone plus finasteride works better for treating hirsutism.